PRESS PLAY
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
Based on 6 episodes we listened to · September 2026
The Top Line connects biopharma research outcomes with pipeline strategy, patent pressure, company forecasts, and competitive risk.
The Top Line follows the business consequences of biopharma science, connecting clinical setbacks and patent expirations to pipeline pressure, revenue forecasts, and competitive position.
Patent cliffs make clinical trial flops sound louder when you're listening for the business stakes.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A measured rare-disease M&A briefing with a clear pipeline cadence and sponsor-backed framing.
The episode centers on Ajay Narasimha's case for why Merum's Blue Jay Therapeutics acquisition fits a rare-disease business that is already built for launch.
A steady read on how patent cliffs are reshaping biopharma guidance.
The segment uses the top 25 biopharma companies' fourth quarter earnings to show how quickly a familiar growth story can turn brittle once blockbuster drugs start losing patent protection.
A muted JPM makes for a clear look at dealmaking, AI hype, and the mood underneath both.
The Top Line treats this year's J.P. Morgan Healthcare Conference as a market that showed up with less spectacle than usual. It works best when it leans into the missing megadeals, because that silence says more than the usual parade of announcements.
Tariff pressure reshaped pharma manufacturing before policy fully landed.
Fraser Kansteiner and Brady McKinney frame tariff pressure as a manufacturing story, and the piece stays steady on that line. It traces how repeated tariff threats pushed drug makers around the world to ramp production in 2025, build inventory, and brace for trade disruption.
A steady look at how community oncology connects practice support, research, and patient access.
Community oncology is where patient access meets the unglamorous work of contracts, referrals, revenue cycle support, and financial administration.
A practical take on AI agents in life sciences, with orchestration and control doing the real work.
This episode treats life sciences AI as plumbing, not magic. The conversation stays on the work that actually matters in regulated settings: adding capacity, speeding up trial work, and keeping people in charge while agents get clear roles, policies, and ownership.
A sharp look at how clinical-trial failures expose the pressure points in biopharma.
James Waldron and Fraser Kahnsteiner use 2025's biggest clinical-trial misses to make a plain point: biopharma keeps running into the same hard walls. The episode does more than tally failures.
A steady read on whether Lilly's GLP-1 lead is as solid as it looks.
The piece puts Eli Lilly's GLP-1 run under a sharp light, using HSBC's downgrade to ask how much of the story still rests on confidence versus the numbers.
Manufacturing signals, translated into business consequences.
Machine shops, ownership, and industrial purpose.
This episode analyzes the Q4 2025 earnings and 2026 guidance of the top 25 biopharma companies, revealing an industry-wide trend toward slower growth or declines.
Xaira Therapeutics, which raised $1 billion, calls itself "an AI company" that discovers medicines rather than a biotech using AI, according to president and COO Jeff Yonker.
Host Irina Lul interviews Ash, a Senior Medical Affairs Lead, and Mark, a researcher with 25+ years of experience, in a sponsored episode from RTI Health Solutions.
John O'Brien, CEO of the National Pharmaceutical Council, tells Burson's Kristen Cahill that the U.S.
KPMG's Kristen Pothier tells Fierce Pharma's Fraser Kahnsteiner that 2026 dealmaking is shaped by the "proof over promise" theme of KPMG's new healthcare and life sciences investment outlook, after a choppy 2025 of lower deal volume.
Fierce Biotech and Fierce Pharma reporters analyze their 2025 report on the biggest clinical trial failures, focusing on high-profile setbacks at Novo Nordisk, Sanofi, Johnson & Johnson, and Roche.
Kirk Kaminsky, a McKesson executive, discusses the growing role of community oncology in cancer care, explaining how practices are adapting to rapid scientific change, leveraging clinical trials, and integrating AI.
An interview with Atradius risk underwriter Brady McKinney about a new report analyzing how Trump administration tariff threats drove a global surge in pharmaceutical manufacturing in 2025.
Host Chris Hayden interviews Sue Bodine, president-elect of the American Physiological Society, about the foundational role of physiology in biotech innovation.
This episode analyzes the FDA's drug approval trends in 2025, highlighting how agency layoffs and leadership changes initially slowed approvals before a recovery in the second half.
The hosts break down Fierce Pharma's annual report on the most anticipated drug launches of 2026, led by next-generation obesity medications from Novo Nordisk and Eli Lilly projected to generate tens of billions in sales.
Clinical trial surprises are the worry, especially when they land at the 11th hour.
The episode analyzes a surprising HSBC analyst report that downgrades Eli Lilly's stock, challenging the prevailing bullish narrative around its dominance in the GLP-1 obesity drug market.
Ajay Narasimha, SVP at Merum Pharmaceuticals, discusses the company's recent acquisition of Blue Jay Therapeutics and its strategic fit.
This episode explores the shift in pharma from product approval to value demonstration, focusing on how to communicate HEOR and real-world evidence effectively.
Salesforce's Mark Sullivan discusses practical AI implementation in life sciences, moving beyond hype to address data challenges, regulatory compliance, and creating 'unlimited' AI workforces.
The episode analyzes the 2026 J.P.
Fierce Pharma's Angus Liu interviews Harpreet Singh, Chief Medical Officer at Precision for Medicine, about the Annals of Internal Medicine article by CBER director Vinay Prasad and colleagues on autoimmune CAR-T.
A biopharma industry news podcast featuring an interview with Roivant CEO discussing China's role in biotech.
This episode analyzes the year-over-year changes in the top 10 pharma companies' R&D budgets for 2025, revealing shifts in spending and strategic priorities.
A sponsored episode of The Top Line featuring an interview with Dennis Johnson, CEO of Grand River Septic Manufacturing, discussing his background in sterile filling and the future of the CDMO space.
Host Chris Hayden interviews Josh Smiley, President of Zai Lab, about shifts in the Chinese biotech landscape and the company's strategy.
A roundtable discussion with three biotech CEOs on investment recovery, manufacturing challenges, and direct-to-consumer models in the biopharma industry.
A year-end review of biopharma and healthcare industry trends, including federal research funding, FDA changes, vaccine policy, and dealmaking.
This episode explores how Walgreens partners with biopharma companies to leverage real-world data for improved patient outcomes and business decisions.
A weekly news roundup analyzing the biggest business stories in biopharma and medtech, including Q1 earnings and gene therapy conference highlights.
This episode analyzes the impact of Trump administration tariffs on the life sciences industry, featuring an interview with a KPMG sector leader.
A sponsored episode discussing drug delivery partnerships and the needs of pharma and biotech companies with a focus on aseptic manufacturing.